Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency
Matej Rakusa, Tomaz Kocjan · 2026
Read Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency by Matej Rakusa, Tomaz Kocjan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625649.txt.
Description
Matej Rakusa and Tomaz Kocjan present a 2026 case report on a young woman with a rare bone and phosphate disorder. Her gene fault makes the kidneys waste phosphate, which softens bone. Low iron can worsen the fault by raising the hormone that drives the waste.
The patient, aged nineteen, had severe soft bone, iron poor blood, and a thigh bone break that failed to heal on standard care. A newer drug that blocks that hormone was used as a bridge. Pain and stiffness fell fast, and she walked on her own within four months. Bone density rose a lot over the next year. Phosphate levels swung and needed dose care with iron. The authors give the first full report of this use.
Catalog record
| CREATOR | Matej Rakusa, Tomaz Kocjan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |